Linker Information
General Information of This Linker
| Linker ID |
LIN0SBGBK
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
ADC-P1 BGB-C-269 Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C37H51N7O15
|
|||||
| Isosmiles |
O=C(NCC(NCC(N[C@@H](CC1=CC=CC=C1)C(NCC(O)=O)=O)=O)=O)[C@@H](NC(CCCCCN2C(C=CC2=O)=O)=O)CCC(NC[C@H](O3)[C@H](O)[C@@H](O)[C@H](O)[C@H]3CO)=O
|
|||||
| InChI |
InChI=1S/C37H51N7O15/c45-20-25-34(55)35(56)33(54)24(59-25)16-38-26(46)11-10-22(42-27(47)9-5-2-6-14-44-30(50)12-13-31(44)51)36(57)40-17-28(48)39-18-29(49)43-23(37(58)41-19-32(52)53)15-21-7-3-1-4-8-21/h1,3-4,7-8,12-13,22-25,33-35,45,54-56H,2,5-6,9-11,14-20H2,(H,38,46)(H,39,48)(H,40,57)(H,41,58)(H,42,47)(H,43,49)(H,52,53)/t22-,23-,24-,25+,33-,34+,35+/m0/s1
|
|||||
| InChIKey |
WSSARPLLWUREJB-HENUYNGUSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
833.849
|
Polar area
|
339.43
|
||
|
Complexity
|
1598.298893
|
xlogp Value
|
-5.1439
|
|||
|
Heavy Count
|
59
|
Rot Bonds
|
24
|
|||
|
Hbond acc
|
14
|
Hbond Donor
|
11
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BGA0084 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.19 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
NCI-H2122 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H2122 cells | CVCL_1531 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.38 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
MKN45 cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.85 nM
|
Positive CEA expression (CEA+++/++) | ||
| Method Description |
Ls147T cells were plated at a density of 5000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Colon adenocarcinoma | Ls147T cells | CVCL_1384 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
25 nM
|
Negative CEA expression (CEA-) | ||
| Method Description |
MDA-MB-231 cells were plated at a density of 2000 cells per well and the next day were treated with payload compounds (5x dilution) for 6 days.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||